FDA clears ARKRAY's new GLUCOCARD Vital blood glucose monitoring system

Nov 5 2009

ARKRAY, Inc., the world's 5th largest manufacturer of diabetes self-monitoring systems, today announced that it has received 510(k) clearance from the US Food and Drug Administration for its new GLUCOCARD Vital blood glucose monitoring system.

The new meter and strip platform, which ARKRAY will make available for distribution in early December, is expected to be a significant complement to the existing GLUCOCARD line of products, and will be ideal for the home medical equipment (HME), durable medical equipment (DME), mail order and managed care markets.

"We're very excited about the latest addition to our GLUCOCARD brand," said Jonathan Chapman, President of ARKRAY, USA. "The Vital meets all of ARKRAY's rigorous design and performance standards. And we can offer it at a price point that will make it an ideal solution for our customers to use in competitive bidding."

The new GLUCOCARD Vital meter and strip platform is highly accurate, auto-coded, requires only 0.5 microliter of blood, holds 250 dowloadable tests in its memory and has a glucose oxydase (GO) strip chemistry that is not affected by interferences that cause testing errors in other common test strips.

The Vital, along with all GLUCOCARD brands, are backed by ARKRAY's unique YouChoose((TM)) wellness program, a comprehensive education and support system that includes printed tools, videos, recipes and an integrated website designed to help patients manage their diabetes.